MeSH D018295 - basal cell neoplasms
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Roche | Vismodegib | Erivedge | 2013-07-12 | $303.263 M | Q4/22-Q3/23 | |
| Sun Pharmaceutical Industries | Sonidegib | Odomzo | 2015-08-14 | |||
| Viatris | Imiquimod | Aldara | 1998-09-18 |
Clinical Trials
Historical Success Rate
Phase 1
58%14/24
Phase 2
24%7/29
Phase 3
17%1/6
Approved: 0Overall Success rate: 2%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use